Protagenic Therapeutics, Inc.new (PTIX): Nasdaq/NYSE listing notice — Protagenic: Nasdaq non-compliance for late 10-Q; auditor changed; PT00114 Phase I dosing complete

Protagenic Therapeutics, Inc.new

Dismissed MaloneBailey as auditor, engaged Green Growth CPAs as new independent auditor effective August 7, 2025.
Received Nasdaq deficiency notice on Aug 20, 2025 due to late filing of Q2 2025 Form 10-Q; trading continues under PTIX.
Expects to file overdue 10-Q soon; will submit compliance plan within 60 days if needed.
Completed first dose injection for all subjects in multiple-dose portion of Phase I trial of PT00114; topline safety data expected by end of September.

item 3.01 item 4.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.99

Protagenic Therapeutics, Inc.new dismissed MaloneBailey, LLP as its auditor.

Action: dismissal
Auditor: MaloneBailey, LLP
Successor: Green Growth CPAs

Exact text from the filing

On August 7, 2025, MaloneBailey, LLP (“MaloneBailey”) was dismissed as the independent registered public accounting firm of the Company.

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

August 20, 2025, the Company received a notice (the “Notification Letter”) from the Nasdaq Listing Qualifications department (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of the Form 10-Q. The notice does not immediately effect the listing or trading of the Company’s securities, which continue to trade on the Nasdaq Capital Market under the symbol “PTIX.” The Company intends to submit a plan to regain compliance within 60 calendar days of the Notification Letter, and Nasdaq may grant an exception of up to 180 calendar day

View on SEC.gov

19 auditor changes filed in the last 30 days. Browse all auditor changes →

Protagenic Therapeutics, Inc.new filing history →

Source: SEC EDGAR

accession 0001641172-25-025274

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.